Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine

Infection and Immunity

Volumn 66, Issue 11, 1998, Pages 5450-5456

  Rubinstein, Leonard J ^a,c   García Ojeda, Pablo A ^a   Michon, Francis ^b,d   Jennings, Harold J ^b   Stein, Kathryn E ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^c MERCK RESEARCH LABORATORIES   (United States)

^d North American Vaccine Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OUTER MEMBRANE PROTEIN; POLYSACCHARIDE; TOXOID; VACCINE;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE ACTIVATION; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CELL SUBPOPULATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MEMORY CELL; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0032412386     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.11.5450-5456.1998     Document Type: Article

References (10)

1. Aaberge, I. S., and M. Løvik. 1995. The antibody response to secondary immunization with pneumococcal polysaccharides in mice. Scand. J. Immunol. 42:617-625.
2. Ahonkhai, V. I., L. J. Lukacs, L. C. Jonas, H. Matthews, P. P. Vella, R. W. Ellis, J. M. Staub, K. T. Dolan, C. M. Rusk, G. B. Calandra, and R. J. Gerety. 1990. Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) (PedvaxHIB™): clinical evaluation. Pediatrics 85:676-681.
3. Alonso DeVelasco, E., B. A. T. Dekker, A. F. M. Verheul, R. G. Feldman, J. Verhoef, and H. Snippe. 1995. Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice. J. Infect. Dis. 172:562-565.
4. Anderson, E. L., T. Bowers, C. M. Mink, D. J. Kennedy, R. B. Belshe, H. Harakeh, L. Pais, P. Holder, and G. M. Carlone. 1994. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect. Immun. 62:3391-3395.
5. Avery, O. T., and W. F. Goebel. 1931. Chemo-immunological studies on conjugated carbohydrate-proteins. V. The immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III pneu-mococcus with foreign protein. J. Exp. Med. 54:437-447.
6. Barbour, M. L. 1996. Conjugate vaccines and the carriage of Haemophilus influenzae type B. Emerg. Infect. Dis. 2:176-182.
7. Beuvery, E. C., F. Miedema, R. van Delft, and J. Haverkamp. 1983. Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines. Infect. Immun. 40:39-45.
8. Beuvery, E. C., R. W. van Delft, F. Miedema, V. Kanhai, and J. Nagel. 1983. Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice. Infect. Immun. 41:609-617.
9. Bhattacharjee, A. K., H. J. Jennings, C. P. Kenny, A. Martin, and I. C. P. Smith. 1975. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroup B and C with carbon 13 nuclear magnetic resonance. J. Biol. Chem. 250:1926-1932.
10. Black, S. B., H. R. Shinefield, B. Fireman, et al. 1991. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. Pediatr. Infect. Dis. J. 10:97-104.